NEW YORK, Dec. 17, 2021 /PRNewswire/ -- Arbor Rapha Capital
Bioholodings Corp. I (NASDAQ: ARCKU) (the "Company") today
announced that, commencing December 20, 2021, holders of the
units sold in the Company's initial public offering of 17,250,000
units, including the issuance of 2,250,000 units as a result of the
underwriter's exercise of its option to purchase additional units
in full, completed on November 2, 2021, may elect to
separately trade the shares of Class A common stock and redeemable
warrants included in the units. Those units not separated will
continue to trade on The Nasdaq Stock Market LLC (the "Nasdaq")
under the symbol "ARCKU," and the shares of Class A common stock
and redeemable warrants that are separated will trade on the Nasdaq
under the symbols "ARCK" and "ARCKW," respectively. No fractional
warrants will be issued upon separation of the units and only whole
warrants will trade. Holders of units will need to have their
brokers contact Continental Stock Transfer & Trust Company, the
Company's transfer agent, in order to separate the units into
shares of Class A common stock and redeemable warrants.
The Company is a blank check company formed for the purpose of
effecting a merger, capital stock exchange, asset acquisition,
stock purchase, reorganization or similar business combination with
one or more businesses.
The units were initially offered by the Company in an
underwritten offering. Cantor Fitzgeral & Co. acted as the sole
book-running manager for the offering.
The offering was made only by means of a prospectus, copies of
which may be obtained for free from the U.S. Securities and
Exchange Commission (the "SEC") website at www.sec.gov or by
contacting Cantor Fitzgeral & Co., Attention: Capital Markets,
c/o Cantor Fitzgerald & Co., 499 Park Avenue, 5th Floor,
New York, New York 10022, or by
email at prospectus@cantor.com.
Forward Looking Statements
This press release may include "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical fact
included in this press release are forward-looking statements. When
used in this press release, words such as "anticipate," "believe,"
"estimate," "expect," "intend" and similar expressions, as they
relate to us or our management team, identify forward-looking
statements. Such forward-looking statements are based on the
beliefs of management, as well as assumptions made by, and
information currently available to, the Company's management.
Actual results could differ materially from those contemplated by
the forward-looking statements as a result of certain factors
detailed in the Company's filings with the SEC. All subsequent
written or oral forward-looking statements attributable to us or
persons acting on our behalf are qualified in their entirety by
this paragraph. Forward-looking statements are subject to numerous
conditions, many of which are beyond the control of the Company,
including those set forth in the Risk Factors section of the
Company's registration statement and prospectus relating to the
Company's initial public offering filed with the SEC. The Company
undertakes no obligation to update these statements for revisions
or changes after the date of this release, except as required by
law.
Investor Contact:
Arbor Rapha Capital Bioholdings
Corp. I
info@arcbiocorp.com
https://arcbiocorp.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/arbor-rapha-capital-bioholdings-corp-i-announces-the-separate-trading-of-its-shares-of-class-a-common-stock-and-redeemable-warrants-commencing-december-20-2021-301447604.html
SOURCE Arbor Rapha Capital Bioholdings Corp. I